Advertisement

Short-term results of endovascular surgery with tissue plasminogen activator injection for central retinal vein occlusion

  • Masaaki Ishida
  • Shinya Abe
  • Takuya Nakagawa
  • Atsushi HayashiEmail author
Retinal Disorders
  • 347 Downloads

Abstract

Purpose

To examine the effects of retinal endovascular surgery (REVS) with tissue plasminogen activator injection into the retinal vein in central retinal vein occlusion (CRVO) eyes.

Methods

Sixteen consecutive CRVO patients with macular edema and decreased visual acuity who were referred to Toyama University Hospital between March 2014 and February 2016 were included in this study. Changes in visual acuity (VA) and central retinal thickness (CRT) were evaluated up to 6 months after REVS. Staining and leakage of the retinal veins in fluorescein angiography (FA) was graded in nine patients.

Results

Ten of 16 eyes were determined to be non-ischemic while the remaining six were ischemic. The mean logarithm of the minimum angle of resolution (logMAR) of VA was significantly improved from 0.98 ± 0.58 (mean ± standard deviation) at baseline to 0.78 ± 0.61 at 3 months (p = 0.002), and 0.64 ± 0.60 at 6 months (p = 0.003) after REVS. At 6 months, VA was improved in eight eyes (50%), while the other eight (50%) showed no change; none showed worsening. In the 10 eyes with non-ischemic CRVO, the mean VA was significantly improved at 6 months (p = 0.002), whereas no improvement was found in the six eyes with ischemic CRVO, . In all eyes, the mean CRT was significantly improved from 804 ± 343 μm at baseline to 506 ± 304 μm at 2 months (p = 0.014), 332 ± 229 μm at 3 months (p = 0.0001), and 305 ± 235 μm at 6 months (p = 0.00001). The postoperative complications observed were prolonged vitreous hemorrhage in one eye and neovascular glaucoma in two eyes. For postoperative recurrence of macular edema, sub-tenon injection of triamcinolone acetonide was given to five eyes, and intravitreal injection of an anti-VEGF agent was given to five eyes. Pan-retinal photocoagulation was performed on six eyes with ischemic type CRVO. The FA score was significantly improved after REVS (p = 0.018).

Conclusions

REVS using a specially made micro-needle may be a surgical treatment option for non-ischemic CRVO, but it did not seem effective for ischemic CRVO.

Keywords

Central retinal vein occlusion Retinal endovascular surgery Tissue plasminogen activator Vitreous surgery 

Notes

Compliance with ethical standards

Funding

No funding was received for this research.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study. For this type of study formal consent is not required.

Supplementary material

ESM 1

Injection of tPA solution into retinal vein at the optic disc (MP4 187,536 kb)

References

  1. 1.
    Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124–1133.e1CrossRefPubMedGoogle Scholar
  2. 2.
    Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J et al (2016) Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 123(5):1101–1111CrossRefPubMedGoogle Scholar
  3. 3.
    Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C et al (2013) VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 97(3):278–284CrossRefPubMedGoogle Scholar
  4. 4.
    Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, RETAIN Study Group et al (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121(1):209–219CrossRefPubMedGoogle Scholar
  5. 5.
    Campochiaro PA, Hafiz G, Mir TA et al (2015) Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology 122(7):1426–1437CrossRefPubMedGoogle Scholar
  6. 6.
    Green WR, Chan CC, Hutchins GM et al (1981) Central retinal vein occlusion: a prospective histopathologic study of 20 eyes in 28 cases. Trans Am Ophthalmol Soc 79:371–442PubMedPubMedCentralGoogle Scholar
  7. 7.
    Allf BE, de Juan E Jr (1987) In vivo cannulation of retinal micropuncture of retinal vessels. Graefes Arch Clin Exp Ophthalmol 225:221–225CrossRefPubMedGoogle Scholar
  8. 8.
    Tameesh MK, Lakhanpal RR, Fujii GY, Javaheri M, Shelley TH et al (2004) Retinal vein cannulation with prolonged infusion of tissue plasminogen activator (t-PA) for the treatment of experimental retinal vein occlusion in dogs. Am J Ophthalmol 138(5):829–839CrossRefPubMedGoogle Scholar
  9. 9.
    Tang WM, Han DP (2000) A study of surgical approaches to retinal vascular occlusions. Arch Ophthalmol 118(1):138–143CrossRefPubMedGoogle Scholar
  10. 10.
    Hattenbach LO, Puchta J, Hilgenberg I (2012) Experimental endoscopic endovascular cannulation: a novel approach to thrombolysis in retinal vessel occlusion. Invest Ophthalmol Vis Sci 53:42–46CrossRefPubMedGoogle Scholar
  11. 11.
    Weiss JN (1998) Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol 126:142–144CrossRefPubMedGoogle Scholar
  12. 12.
    Weiss JN, Bynoe LA (2001) Injection of tissue Plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 108:2249–2257CrossRefPubMedGoogle Scholar
  13. 13.
    Bynoe LA, Hutchins RK, Lazarus HS et al (2005) Retinal endovascular surgery for central retinal vein occlusion. Retina 25:625–632CrossRefPubMedGoogle Scholar
  14. 14.
    Feltgen N, Junker B, Agostini H, Hansen LL (2007) Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study. Ophthalmology 114(4):716–723CrossRefPubMedGoogle Scholar
  15. 15.
    Kadonosono K, Yamane S, Arakawa A et al (2011) An experimental study of retinal endovascular surgery with a microfabricated needle. Invest Ophthalmol Vis Sci 52:5790–5793CrossRefPubMedGoogle Scholar
  16. 16.
    Kadonosono K, Yamane S, Arakawa A et al (2013) Endovascular cannulation with a microneedle for central retinal vein occlusion. JAMA Ophthalmol 131:783–786CrossRefPubMedGoogle Scholar
  17. 17.
    Keino H, Okada AA, Watanabe T, Taki W (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol 95(9):1245–1250CrossRefPubMedGoogle Scholar
  18. 18.
    Hayreh SS (2003) Management of central retinal vein occlusion. Ophthalmologica 217:167–188CrossRefPubMedGoogle Scholar
  19. 19.
    Hahn P, Mruthyunjaya P, Fekrat S (2013) Central retinal vein occlusion, 5th edn. Elsevier, London, pp pp1039–pp1049Google Scholar
  20. 20.
    Hattenbach LO, Friedrich Arndt C, Lerche R, Scharrer I, Baatz H, Margaron F, Richard G, Behrens-Baumann W, Ohrloff C (2009) Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 29(7):932–940CrossRefPubMedGoogle Scholar
  21. 21.
    Brynskov T, Kemp H, Sørensen TL (2014) Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice. Retina 34(8):1637–1643CrossRefPubMedGoogle Scholar
  22. 22.
    Vaz-Pereira S, Marques IP, Matias J et al (2017) Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal. Eur J Ophthalmol 28:0. doi: 10.5301/ejo.5000943 Google Scholar
  23. 23.
    Mir TA, Kherani S, Hafiz G et al (2016) Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion. Ophthalmology 123(3):625–634CrossRefPubMedGoogle Scholar
  24. 24.
    Chuang LH, Wang NK, Chen YP et al (2013) Vitrectomy and panretinal photocoagulation reduces the occurrence of neovascular glaucoma in central retinal vein occlusion with vitreous hemorrhage. Retina 33(4):798–802CrossRefPubMedGoogle Scholar
  25. 25.
    Elman MJ, Raden RZ, Carrigan A (2001) Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc 99:219–221PubMedPubMedCentralGoogle Scholar
  26. 26.
    Ghazi NG, Noureddine B, Haddad RS, Jurdi FA, Bashshur ZF (2003) Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. Retina 23(6):780–784CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Masaaki Ishida
    • 1
  • Shinya Abe
    • 1
  • Takuya Nakagawa
    • 1
  • Atsushi Hayashi
    • 1
    Email author
  1. 1.Department of OphthalmologyUniversity of ToyamaToyamaJapan

Personalised recommendations